Literature DB >> 2360832

Efficacy of SCH39304 and fluconazole in a murine model of disseminated coccidioidomycosis.

K V Clemons1, L H Hanson, A M Perlman, D A Stevens.   

Abstract

The efficacies of SCH39304 (SCH) and fluconazole (FLU) were tested in a murine model of coccidioidomycosis. CD-1 mice were infected with Coccidioides immitis and dosed with SCH at 2, 10, 25, or 50 mg/kg per day or FLU at 10 or 100 mg/kg per day. Survival was enhanced (P less than 0.001) by both drugs at all doses. Residual burdens of C. immitis in the organs of mice treated with SCH at 25 or 50 mg/kg per day were lower than in mice treated with FLU at 100 mg/kg per day (P less than 0.001). These results indicate that SCH is an effective therapy for coccidioidomycosis and is superior to FLU in this comparison.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2360832      PMCID: PMC171724          DOI: 10.1128/AAC.34.5.928

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Obfuscation of the activity of antifungal antimicrobics by culture media.

Authors:  P D Hoeprich; P D Finn
Journal:  J Infect Dis       Date:  1972-10       Impact factor: 5.226

2.  The new generation of antifungal drugs.

Authors:  D A Stevens
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-12       Impact factor: 3.267

3.  Pharmacology and toxicity of high-dose ketoconazole.

Authors:  A M Sugar; S G Alsip; J N Galgiani; J R Graybill; W E Dismukes; G A Cloud; P C Craven; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

4.  Treatment of murine coccidioidal meningitis with fluconazole (UK 49,858).

Authors:  J R Graybill; S H Sun; J Ahrens
Journal:  J Med Vet Mycol       Date:  1986-04

5.  Systemic Coccidioides immitis infection in nude and beige mice.

Authors:  K V Clemons; C R Leathers; K W Lee
Journal:  Infect Immun       Date:  1985-03       Impact factor: 3.441

6.  In vitro susceptibilities of yeasts to a new antifungal triazole, SCH 39304: effects of test conditions and relation to in vivo efficacy.

Authors:  K A McIntyre; J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

7.  Ketoconazole therapy of progressive coccidioidomycosis. Comparison of 400- and 800-mg doses and observations at higher doses.

Authors:  J N Galgiani; D A Stevens; J R Graybill; W E Dismukes; G A Cloud
Journal:  Am J Med       Date:  1988-03       Impact factor: 4.965

8.  Ketoconazole treatment of coccidioidal meningitis.

Authors:  J R Graybill; D A Stevens; J N Galgiani; A M Sugar; P C Craven; C Gregg; M Huppert; G Cloud; W E Dismukes
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

9.  Treatment of mycoses with itraconazole.

Authors:  R M Tucker; P L Williams; E G Arathoon; D A Stevens
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

10.  Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis.

Authors:  R M Tucker; P L Williams; E G Arathoon; B E Levine; A I Hartstein; L H Hanson; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

View more
  17 in total

Review 1.  Murine models of blastomycosis, coccidioidomycosis, and histoplasmosis.

Authors:  K N Sorensen; K V Clemons; D A Stevens
Journal:  Mycopathologia       Date:  1999       Impact factor: 2.574

2.  Comparison of SCH 39304 and its isomers, RR 42427 and SS 42426, for treatment of murine cryptococcal and coccidioidal meningitis.

Authors:  R Allendoerfer; R R Yates; A J Marquis; D Loebenberg; M G Rinaldi; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

3.  Comparison of SCH 39304, fluconazole, and ketoconazole for treatment of systemic infections in mice.

Authors:  A Cacciapuoti; D Loebenberg; R Parmegiani; B Antonacci; C Norris; E L Moss; F Menzel; T Yarosh-Tomaine; R S Hare; G H Miller
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

4.  Pharmacokinetics of the triazole antifungal agent genaconazole in healthy men after oral and intravenous administration.

Authors:  P Mojaverian; E Radwanski; M B Affrime; M N Cayen; C C Lin
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

5.  Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis.

Authors:  J E Lutz; K V Clemons; B H Aristizabal; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

6.  Activities of the triazole SCH 51048 against Coccidioides immitis in vitro and in vivo.

Authors:  K V Clemons; M E Homola; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

7.  SCH 39304 in the treatment of acute or established murine pulmonary blastomycosis.

Authors:  E Brummer; L H Hanson; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

8.  Efficacies of sordarin derivatives GM193663, GM211676, and GM237354 in a murine model of systemic coccidioidomycosis. p6.

Authors:  K V Clemons; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

9.  Interactions of amphotericin B and SCH 39304 in the treatment of experimental murine candidiasis: lack of antagonism of a polyene-azole combination.

Authors:  A M Sugar
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

10.  Comparative efficacy of amphotericin B colloidal dispersion and amphotericin B deoxycholate suspension in treatment of murine coccidioidomycosis.

Authors:  K V Clemons; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.